Recommended Dose of Apixaban (Eliquis) for Atrial Fibrillation
For most adults with non-valvular atrial fibrillation, the recommended dose of apixaban is 5 mg orally twice daily. 1
Standard Dosing Algorithm
Start with 5 mg twice daily unless the patient meets specific dose reduction criteria. The decision is straightforward and based on objective parameters 2, 3, 4, 5:
Dose Reduction to 2.5 mg Twice Daily Required When:
Any TWO of the following three criteria are present:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This is a critical distinction: Patients with only ONE of these characteristics should receive the standard 5 mg twice daily dose, not the reduced dose. Evidence from the ARISTOTLE trial demonstrates that patients with a single dose-reduction criterion maintain consistent safety and efficacy with the 5 mg dose compared to warfarin 6. The 5 mg dose remains appropriate and should not be empirically reduced based on clinical judgment alone.
Renal Function Considerations
For patients with normal to moderate renal impairment (CrCl >30 mL/min), use the standard dosing algorithm above (5 mg or 2.5 mg based on the two-out-of-three criteria) 2, 3, 4, 5.
For patients with severe renal impairment (CrCl 15-30 mL/min), guidelines provide no specific recommendation, though the FDA label allows for continued use of the standard dosing algorithm 3, 1.
For patients with end-stage renal disease on hemodialysis, the FDA label indicates 5 mg twice daily, reduced to 2.5 mg twice daily if age ≥80 years OR body weight ≤60 kg (note: only ONE criterion needed in dialysis patients, not two) 2, 3, 1.
Critical Pitfalls to Avoid
Off-label dose reduction is common but inappropriate. Studies show that 60-61% of patients receiving reduced-dose apixaban do not meet the labeling criteria for dose reduction 7, 8. This inappropriate underdosing is associated with higher mortality without clear reductions in bleeding risk 9, 8.
Do not reduce the dose based on:
- Advanced age alone (without meeting two criteria)
- Low body weight alone (without meeting two criteria)
- Elevated creatinine alone (without meeting two criteria)
- Perceived bleeding risk
- Concomitant antiplatelet therapy (though this increases bleeding risk, it is not a dose-reduction criterion)
Hepatic Impairment
No dose adjustment is needed for mild hepatic impairment (Child-Pugh A). Apixaban is not recommended for severe hepatic impairment (Child-Pugh C). For moderate hepatic impairment (Child-Pugh B), dosing recommendations cannot be provided due to limited data 1.
Renal Function Monitoring
Assess creatinine clearance using the Cockcroft-Gault method before initiating apixaban and recheck at least annually or when clinically indicated 2, 3.
Drug Interactions Requiring Attention
Avoid concomitant use with dual P-glycoprotein and strong CYP3A4 inhibitors or inducers, particularly in patients with chronic kidney disease, as these may require dose adjustment or avoidance 2, 3.